Lomustine

Generic Name: Lomustine

Brand Names: Ceenu, Gleostine

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₆ClN_₃O_₂

CAS Number: 13010-47-4

Unique Ingredient Identifier: 7BRF0Z81KG

Background: An alkylating agent of value against both hematologic malignancies and solid tumors.

Indication: For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.

Associated Conditions: Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma

Clinical Trials

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Phase 1

Terminated

Conditions: Relapsed/Recurrent GBM (Phase 2)
Solid Tumors (Phase 1)

Interventions: Drug: USL311
Drug: Lomustine

First Posted Date: 2016-05-06

Last Posted Date: 2021-07-23

Lead Sponsor: Proximagen, LLC

Target Recruit Count: 26

Registration Number: NCT02765165

Locations: 🇺🇸
University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
University of Texas/MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States

and more 3 locations

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Phase 2

Active, not recruiting

Conditions: Medulloblastoma

Interventions: Drug: Cisplatin
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Drug: Lomustine
Procedure: Magnetic Resonance Imaging
Radiation: Radiation Therapy
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2016-03-31

Last Posted Date: 2025-03-19

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 45

Registration Number: NCT02724579

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 193 locations

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

Phase 2

Terminated

Conditions: Glioblastoma Multiforme
Anaplastic Astrocytoma

Interventions: Biological: Toca 511
Drug: Lomustine
Drug: Toca FC
Drug: Temozolomide
Biological: Bevacizumab

First Posted Date: 2015-04-10

Last Posted Date: 2020-02-07

Lead Sponsor: Tocagen Inc.

Target Recruit Count: 403

Registration Number: NCT02414165

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 64 locations

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: Lomustine
Drug: Depatuxizumab mafodotin
Drug: Temozolomide

First Posted Date: 2015-01-22

Last Posted Date: 2020-05-22

Lead Sponsor: AbbVie

Target Recruit Count: 266

Registration Number: NCT02343406

Locations: 🇫🇷
Hopital Pitie Salpetriere /ID# 145887, Paris, France
🇮🇹
Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 140395, Milan, Italy
🇫🇷
CHU-Hopital Avicenne /ID# 137910, Bobigny, Ile-de-France, France

and more 99 locations

Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma

Early Phase 1

Terminated

Conditions: Medulloblastoma

Interventions: Drug: Lomustine
Drug: Vincristine
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Mesna

First Posted Date: 2014-08-08

Last Posted Date: 2021-11-05

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 6

Registration Number: NCT02212574

Locations: 🇺🇸
Ann and Robert H Lurie Children's Hospital of Chicago Hematology/Oncology, Chicago, Illinois, United States
🇺🇸
Children's Hospital Colorado Center for Cancer & Blood Disorders, Aurora, Colorado, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 13 locations

FMISO PET Study of Glioblastoma

Not Applicable

Completed

Conditions: Recurrent Glioblastoma

Interventions: Device: FMISO PET
Device: MRI
Drug: Bevacizumab
Drug: CCNU

First Posted Date: 2014-03-03

Last Posted Date: 2021-07-30

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 11

Registration Number: NCT02076152

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma

Phase 1

Terminated

Conditions: Malignant Glioma (WHO Grade III or IV)

Interventions: Drug: CTO
Drug: Lomustine

First Posted Date: 2013-11-20

Last Posted Date: 2016-08-04

Lead Sponsor: Annick Desjardins

Target Recruit Count: 9

Registration Number: NCT01989052

Locations: 🇺🇸
The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

Phase 1

Completed

Conditions: Recurrent Glioblastoma Multiforme

Interventions: Drug: buparlisib
Drug: carboplatin
Drug: lomustine
Drug: placebo

First Posted Date: 2013-09-04

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 35

Registration Number: NCT01934361

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 3 locations

A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: Bevacizumab
Drug: Lomustine
Drug: Placebo
Radiation: Radiotherapy
Drug: Temozolomide
Drug: SOC Agent

First Posted Date: 2013-05-23

Last Posted Date: 2018-04-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 296

Registration Number: NCT01860638

Locations: 🇦🇹
Medizinische Universität Graz; Universitätsklinik für Neurologie, Graz, Austria
🇷🇴
Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania
🇦🇹
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria

and more 61 locations

Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: AIDS-related Diffuse Mixed Cell Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Lymphoblastic Lymphoma
AIDS-related Small Noncleaved Cell Lymphoma
Stage IV AIDS-related Lymphoma
AIDS-related Diffuse Large Cell Lymphoma
Stage III AIDS-related Lymphoma
AIDS-related Diffuse Small Cleaved Cell Lymphoma
AIDS-related Immunoblastic Large Cell Lymphoma

Interventions: Drug: cyclophosphamide
Drug: lomustine
Drug: etoposide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: procarbazine hydrochloride
Drug: prednisone
Other: laboratory biomarker analysis

First Posted Date: 2013-01-25

Last Posted Date: 2022-10-10

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 7

Registration Number: NCT01775475

Locations: 🇿🇼
University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
🇰🇪
Moi Teaching and Referral Hospital, Eldoret, Kenya

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy